The initiative, Project Optimus, launched in 2021 just as Amgen was seeking to market sotorasib. At the time, the FDA’s leading cancer drug regulator, Richard Pazdur, co-wrote an editorial in ...

Join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization ...

After decades of mostly unsuccessful R&D, Amgen has claimed the first ever ... The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c ...

Amgen points out that the study wasn't statistically ... likely serve as a confirmatory study for the approval of Lumakras (sotorasib) in this heavily pretreated patient population, which was ...

Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved drug in the market-and an experimental drug called FGTI-2734 ...

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a ...

Glickman says Amgen's late-stage pipeline assets, including cancer treatment sotorasib and asthma therapy tezepelumab, are promising growth opportunities. Amgen has already received approval from ...

Now two KRAS inhibitors, Amgen’s sotorasib (Lumakras) and BMS/Mirati’s adagrasib (Krazati), are approved — and many more are in the clinic. But while clinicians had high hopes that these ...